EP Patent

EP2632270A1 — Polymorphs of febuxostat

Assigned to Mapi Pharma Ltd · Expires 2013-09-04 · 13y expired

What this patent protects

The present invention provides new crystalline forms of febuxostat, pharmaceutical compositions comprising same, methods for their preparation and use thereof in treating hyperuricaemia.

USPTO Abstract

The present invention provides new crystalline forms of febuxostat, pharmaceutical compositions comprising same, methods for their preparation and use thereof in treating hyperuricaemia.

Drugs covered by this patent

Patent Metadata

Patent number
EP2632270A1
Jurisdiction
EP
Classification
—
Expires
2013-09-04
Drug substance claim
No
Drug product claim
No
Assignee
Mapi Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.